Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA semaglutide course for weight management means a structured, once-weekly injection programme that typically runs for many months — the licensed schedule starts at a low dose and steps upward over roughly 16–20 weeks before reaching the maintenance dose your prescriber decides is right for you. It is only available in the UK with a valid prescription following a clinical assessment. The decision worth understanding before you start isn't just whether semaglutide might suit you; it's what committing to a full Wegovy course actually looks like — the timeframes, the dose changes, the side-effect picture, and when a prescriber reviews whether to continue.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The titration schedule exists for one reason: tolerance. Semaglutide causes the stomach to empty more slowly and prompts a noticeable drop in appetite, useful effects for weight management, but ones that can cause nausea, particularly in the first few weeks. Starting at 0.25 mg gives your system a chance to settle before the dose climbs.
From there, the standard Wegovy course moves through 0.5 mg, 1.0 mg and 1.7 mg before reaching 2.4 mg, with at least four weeks at each level. That is a minimum of around 16 weeks just to reach maintenance, so if you're weighing up a semaglutide course expecting results within a month, the timeline works differently. The evidence comes from trials lasting 68 weeks or longer, not a few pens.
The MHRA approved a higher 7.2 mg maintenance dose in January 2026, with a dedicated single-dose pen confirmed in April 2026. Whether that dose level is appropriate is a conversation for a prescriber, not a default the course moves toward automatically. You can read the full semaglutide overview on our semaglutide information page if you want the mechanism in more detail, or if you'd like a deeper clinical grounding before starting, our semaglutide training course for UK practitioners covers the pharmacology and prescribing framework in detail.
One checking habit worth building: before each new pen, confirm the dose printed on the label matches what your prescriber approved at your last review. It takes ten seconds and catches the occasional dispensing slip before it matters.
The pivotal STEP 1 trial ran for 68 weeks and recorded an average weight reduction of around 15% with semaglutide 2.4 mg alongside lifestyle changes, as published in the New England Journal of Medicine. Participants who stopped treatment typically saw weight return over the following months, which tells you something important about how a Wegovy course is best thought of: as a sustained medical intervention rather than a fixed-length programme with a clear end date.
NICE recommends semaglutide for adults with a BMI of 35 or above and at least one weight-related condition, and only within a specialist weight management service, for a maximum of two years. Lower BMI thresholds apply for some ethnic backgrounds. That two-year cap under NHS guidance doesn't apply in the same way to private prescribing, but it does underscore that continuing after six months on maintenance should involve a formal review of how much weight has been lost. If the threshold hasn't been reached, a clinician needs to consider whether the course is working well enough to continue. If you want a concise refresher on the evidence base before that conversation, our free online semaglutide training course is a useful starting point.
For context on what a private semaglutide course costs over those months, our Wegovy price comparison page sets out what different providers include in their pricing and what to check before committing.
The most common side effects throughout a semaglutide course are gastrointestinal: nausea, loose stools, constipation, indigestion and, for some people, vomiting. They are most noticeable after a dose increase and typically settle within a week or two as your body adjusts, though they don't always disappear entirely at the higher doses.
Fatigue, headaches and dizziness crop up less often but are reported. Injection-site reactions are generally mild. The NHS semaglutide medicines page lists the full side-effect profile and, critically, the symptoms that need prompt medical attention, pancreatitis is rare but serious, so severe stomach pain that spreads to your back should never be sat on.
Staying hydrated matters throughout a course, particularly in the early weeks when nausea can put people off drinking enough. Protein intake is worth keeping up too; appetite reduction can otherwise lead to muscle loss alongside fat loss. These are things a prescriber or dietitian can help you plan around, and they're a normal part of what good aftercare looks like. Our semaglutide 1 mg guidance page goes into more detail on managing this transition point, which is where side effects can resurface as the dose increases.
A course isn't just a supply of pens. It's a sequence of clinical reviews: an assessment before the first prescription, a review at each dose change, a check at six months on maintenance and an ongoing appraisal of how things are going. That structure matters because the prescriber can spot when a dose needs to slow, when a side effect needs addressing, or when something has changed in your health picture that affects whether semaglutide remains appropriate.
At nume, a GPhC-registered Independent Prescriber reads every consultation personally, your case isn't processed by software. Our clinical team, led by our clinical director, oversees the review process for every patient. You can verify our pharmacy on the GPhC register at pharmacyregulation.org using our premises number 9012878.
If you're considering treatment and want to understand what the full Wegovy treatment pathway looks like in practice, or if you're curious about how semaglutide compares to other weight-loss treatment options, both pages are worth reading before your consultation. When you're ready, you can start the process through our free consultation page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.